317 related articles for article (PubMed ID: 33299647)
1. Role of chromosomal instability and clonal heterogeneity in the therapy response of breast cancer cell lines.
Vargas-Rondón N; Pérez-Mora E; Villegas VE; Rondón-Lagos M
Cancer Biol Med; 2020 Nov; 17(4):970-985. PubMed ID: 33299647
[TBL] [Abstract][Full Text] [Related]
2. Extreme chromosomal instability forecasts improved outcome in ER-negative breast cancer: a prospective validation cohort study from the TACT trial.
Jamal-Hanjani M; A'Hern R; Birkbak NJ; Gorman P; Grönroos E; Ngang S; Nicola P; Rahman L; Thanopoulou E; Kelly G; Ellis P; Barrett-Lee P; Johnston SR; Bliss J; Roylance R; Swanton C
Ann Oncol; 2015 Jul; 26(7):1340-6. PubMed ID: 26003169
[TBL] [Abstract][Full Text] [Related]
3. Patterns of Chromosomal Instability and Clonal Heterogeneity in Luminal B Breast Cancer: A Pilot Study.
Camargo-Herrera V; Castellanos G; Rangel N; Jiménez-Tobón GA; Martínez-Agüero M; Rondón-Lagos M
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674062
[TBL] [Abstract][Full Text] [Related]
4. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer.
Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C
J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662
[TBL] [Abstract][Full Text] [Related]
5. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
Roylance R; Endesfelder D; Gorman P; Burrell RA; Sander J; Tomlinson I; Hanby AM; Speirs V; Richardson AL; Birkbak NJ; Eklund AC; Downward J; Kschischo M; Szallasi Z; Swanton C
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2183-94. PubMed ID: 21784954
[TBL] [Abstract][Full Text] [Related]
6. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer.
Schramm A; Schochter F; Friedl TWP; de Gregorio N; Andergassen U; Alunni-Fabbroni M; Trapp E; Jaeger B; Heinrich G; Camara O; Decker T; Ober A; Mahner S; Fehm TN; Pantel K; Fasching PA; Schneeweiss A; Janni W; Rack BK;
Clin Breast Cancer; 2017 Jul; 17(4):279-285. PubMed ID: 28190761
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of combination of Trastuzumab (Herceptin) and Tamoxifen in breast cancer.
Wang CX; Koay DC; Edwards A; Lu Z; Mor G; Ocal IT; Digiovanna MP
Breast Cancer Res Treat; 2005 Aug; 92(3):251-63. PubMed ID: 16155796
[TBL] [Abstract][Full Text] [Related]
9. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX
Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075
[TBL] [Abstract][Full Text] [Related]
10. Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes.
Rondón-Lagos M; Rangel N; Di Cantogno LV; Annaratone L; Castellano I; Russo R; Manetta T; Marchiò C; Sapino A
Endocr Relat Cancer; 2016 Aug; 23(8):635-50. PubMed ID: 27357940
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
[TBL] [Abstract][Full Text] [Related]
12. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
13. Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping.
Whitworth P; Beitsch P; Mislowsky A; Pellicane JV; Nash C; Murray M; Lee LA; Dul CL; Rotkis M; Baron P; Stork-Sloots L; de Snoo FA; Beatty J
Ann Surg Oncol; 2017 Mar; 24(3):669-675. PubMed ID: 27770345
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor α signalling and results in tamoxifen insensitive proliferation.
Moerkens M; Zhang Y; Wester L; van de Water B; Meerman JH
BMC Cancer; 2014 Apr; 14():283. PubMed ID: 24758408
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance.
Leary AF; Drury S; Detre S; Pancholi S; Lykkesfeldt AE; Martin LA; Dowsett M; Johnston SR
Clin Cancer Res; 2010 Mar; 16(5):1486-97. PubMed ID: 20179226
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
Loi S; Sirtaine N; Piette F; Salgado R; Viale G; Van Eenoo F; Rouas G; Francis P; Crown JP; Hitre E; de Azambuja E; Quinaux E; Di Leo A; Michiels S; Piccart MJ; Sotiriou C
J Clin Oncol; 2013 Mar; 31(7):860-7. PubMed ID: 23341518
[TBL] [Abstract][Full Text] [Related]
18. Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.
Smid M; Hoes M; Sieuwerts AM; Sleijfer S; Zhang Y; Wang Y; Foekens JA; Martens JW
Breast Cancer Res Treat; 2011 Jul; 128(1):23-30. PubMed ID: 20632083
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression.
Giordano C; Catalano S; Panza S; Vizza D; Barone I; Bonofiglio D; Gelsomino L; Rizza P; Fuqua SA; Andò S
Oncogene; 2011 Sep; 30(39):4129-40. PubMed ID: 21499302
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
